EXHIBIT 99.1

        CAVIT SCIENCES, INC. AND AMERICARE NUTRITIONAL DIVISION ANNOUNCE
                       ASSET PURCHASE & ROYALTY AGREEMENT
            TO COMMERCIALIZE FOOD SUPPLEMENT AND HERBAL LINE

     DELRAY BEACH, FL, FEBRUARY 14, 2007--Cavit Sciences, Inc. ("Cavit") (OTCBB:
CVIT) and Daycon Investors  Associates,  Inc.,  Americare  Nutritional  Division
("Americare")  today  announced  the signing of an agreement  enabling  Cavit to
commercialize  a complete food supplement and herbal line for the enhancement of
health.

     Under the  Asset  Purchase  & Royalty  Agreement,  Cavit has  obtained  the
ingredients,  combinations  and proprietary  formulations  which have beneficial
effects  upon  certain  body  conditions,  including,  but not limited to, heart
disease,  cancer,  diabetes,  obesity,  hypertension,  stress, arterial buildup,
cardiovascular diseases, menopausal symptoms and cholesterol.

     Cavit  will  introduce  a full line of  products  to improve  physical  and
psychological  well-being,  enhance the immune system,  improve  memory,  act as
antioxidants,  increase  energy and  maintain a healthy  nervous  system.  Cavit
intends  to  manufacture,  market,  distribute  and  commercialize  a  range  of
supplements  to act as powerful  antioxidants  and immune  enhancers  which have
beneficial effects upon many serious diseases.

     Cavit has agreed to pay Americare  $250,000,  which  includes the knowledge
and expertise of Dr. Joseph P. D'Angelo in developing  and  commercializing  new
products.  Americare is also entitled to receive additional  payments consisting
of royalties upon commercial launch of each product and on net sales.

     "We are very pleased to have  completed this  agreement,  enabling Cavit to
market a line of supplements  resulting from years of research and development,"
said Dr. Joseph P. D'Angelo, President and Chief Executive Officer of Americare.
"We're  planning to offer  additional  products to Cavit through our  continuing
research and development."

     "These products will be a valuable addition to our biotechnology  company,"
said Colm J. King,  President and Chief Executive  Officer of Cavit.  "The Cavit
team intends to make significant headway in building a supplemental  nutritional
market and establishing customer relationships,  especially in the United States
and various  countries where certain  ailments and conditions are more prevalent
than in any other region of the world. Working together, Americare and Cavit can
help meet the needs of individuals  through the enhancement of health by rapidly
advancing  our  products  in these  markets.  We hope our  products  will  offer
valuable  and  beneficial  options and help  improve the quality and duration of
life of millions of individuals throughout the world."

     Cavit  Sciences,  Inc.  ("Cavit")  is a  biotechnology  company  engaged in
developing treatments of cancer and viral infections.  Additional information is
available on the Company's website at: www.cavitsciences.com

     Statements   contained   herein  that  are  not  historical   fact  may  be
forward-looking  statements  within the meaning of Section 27A of the Securities
Act of 1933 and Section 21E of the  Securities  Exchange  Act of 1934,  that are
subject to a variety of risks and uncertainties. There are a number of important

factors  that  could  cause  actual  results  to differ  materially  from  those
projected  or  suggested  in any  forward-looking  statements  made by  Cavit or
Americare  and that could affect  whether and when  Americare  would receive any
payments or royalties under the agreement.  These factors  include,  but are not
limited to: (i) the ability of Cavit to successfully  raise financing,  (ii) the
ability of Cavit to set up its  manufacturing and distribution  facilities,  and
(iii) the ability of Cavit to successfully commercialize its products in certain
markets. Additional factors that would cause actual results to differ materially
from  those  projected  or  suggested  in  any  forward-looking  statements  are
contained  in Cavit's  filings  with the  Securities  and  Exchange  Commission,
including those factors  discussed under the caption "Risk Factors" for Cavit on
Form 10-SB filed on October 16, 2006.

CONTACT:

Colm J. King, CEO      (561) 278-7856
Cavit Sciences, Inc.    www.cavitsciences.com